President Donald Trump announced on September 26 that brand-name and patented pharmaceutical products will face a 100% tariff beginning October 1, unless drugmakers are actively constructing manufacturing facilities in the United States. The sweeping tariff policy represents the administration’s most
The Swiss-based parent company will retain the Polpharma Biologics brand and continue its biosimilars business. Meanwhile, Rezon Bio will operate CDMO services from two facilities in Poland – located in Gdańsk and Duchnice near Warsaw. Proven Infrastructure and Regulatory Standing
An analysis of the CDMOs operating facilities in Europe, by Small Molecule, Biologics and Cell & Gene Therapty
Download the CDMO Periodic Table: 118 essential elements for contract development manufacturing success
HHS Secretary Robert F. Kennedy Jr.’s reconstituted Advisory Committee on Immunization Practices (ACIP) is expected to vote September 18-19 to delay routine hepatitis B vaccination from birth to age 4, potentially ending a 30-year universal newborn vaccination program that has
“The idea is to get the information in real time. And for that, you would go and see what systems you have at hand, what system your CMO is using, and find a joint ‘Safe Space’, which serves both sides.”
The global Contract Development and Manufacturing Organization (CDMO) market growth continues to attract significant analyst attention, with leading research firms providing varying estimates based on different methodological approaches and scope definitions. While individual forecasts range considerably—from conservative manufacturing-focused projections to
“Sustainability isn’t just about doing the right thing. It’s about making smarter, more cost effective decisions that are really building stronger, more reliable supply chains.” Christiane Walker, Product Development Team Lead at Intelsius, believes the pharmaceutical industry stands at a
EXCLUSIVE REPORT From Uncertainty to Strategic Resilience Download this report from External Manufacturing Leaders Basel for candid insights into how European pharma executives are building network supply resilience in an era of geopolitical uncertainty. In August 2025, senior external manufacturing
“CMC topics are often taken a bit late in development. The biggest pitfall is not only it’s going to cost you more, but it’s going to cause delays to your programme. The more you push it, the bigger are the
